vai alle Pubblicazioni
Publications prior to 2004
1. Vianelli N*,
Palandri F*, Polverelli N, Stasi R , Joelsson J, Johansson
E, Ruggeri M, Zaja F, Cantoni S, Catucci AE, Candoni A, Morra E,
Bjorkholm M, Baccarani M, Rodeghiero F. Splenectomy as curative
treatment for Immune Thrombocytopenia (ITP): a retrospective study
of 233 patients with a minimum follow-up of 10 years. Haematologica
2012, accepted for publication.
2. Palandri F,
Polverelli N, Lifrieri F, Catani L, Giannini MB, Baccarani M,
Vianelli N. Romiplostim as early treatment of immune
thrombocytopenia with severe immunodeficiency. Hematol Rep.
2012 May 10;4(2):e10. IF 2.1
3. Luatti S, Castagnetti F,
Marzocchi G, Baldazzi C, Gugliotta G, Iacobucci I, Specchia G,
Zanatta L, Rege-Cambrin G, Mancini M, Abruzzese E, Zaccaria A,
Grimoldi MG, Gozzetti A, Ameli G, Capucci MA, Palka G, Bernasconi
P, Palandri F, Pane F, Saglio G, Martinelli G, Rosti G,
Baccarani M, Testoni N; on behalf of the Gruppo Italiano Malattie
Ematologiche dell'Adulto (GIMEMA) Working Party on CML.
Additional chromosomal abnormalities in Philadelphia-positive
clone: adverse prognostic influence on frontline imatinib therapy:
a GIMEMA Working Party on CML analysis. Blood. 2012 Jul
26;120(4):761-767. IF 10.558
4. Gugliotta G, Castagnetti F,
Palandri F, Baccarani M, Rosti G. Imatinib in chronic
myeloid leukemia elderly patients. Aging (Albany NY). 2011
Dec 27.
5. Palandri F,
Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Very
elderly patients with essential thrombocythaemia: are they a
separate category? A monocentric study on 118 patients older
than 75 years. Br J Haematol. 2011 Oct 8.
6. Palandri F,
Polverelli N, Catani L, Sollazzo D, Ottaviani E, Parisi S,
Baccarani M, Vianelli N. Bleeding in essential thrombocythaemia: a
retrospective analysis on 565 patients. Br J Haematol. 2012
Jan; 56(2):281-4.
7. Rosti G, Castagnetti F,
Gugliotta G, Palandri F, Baccarani M. Physician's guide to
the clinical management of adverse events on nilotinib therapy for
the treatment of CML. Cancer Treat Rev. 2011 Aug 11.
8. Soverini S, Gnani A, De
Benedittis C, Castagnetti F, Gugliotta G, Iacobucci I, Palandri
F, Rosti G, Testoni N, Luatti S, Marzocchi G, Baccarani M,
Martinelli G. Low-level Bcr-Abl mutations are very rare in chronic
myeloid leukemia patients who are in major molecular response on
first-line nilotinib. Leuk Res. 2011 Nov;35(11):1527-9.
9. Rosti G, Castagnetti F,
Gugliotta G, Palandri F, Baccarani M. Second-generation
BCR-ABL inhibitors for frontline treatment of chronic myeloid
leukemia in chronic phase. Crit Rev Oncol Hematol. 2011 May
10.
10. Gugliotta G, Castagnetti F, Palandri
F, Breccia M, Intermesoli T, Capucci A, Martino B, Pregno P,
Rupoli S, Ferrero D, Gherlinzoni F, Montefusco E, Bocchia M,
Tiribelli M, Pierri I, Grifoni F, Marzocchi G, Amabile M, Testoni
N, Martinelli G, Alimena G, Pane F, Saglio G, Baccarani M, Rosti G;
Gruppo Italiano Malattie Ematologiche dell'Adulto CML Working
Party. Frontline imatinib treatment of chronic myeloid
leukemia: no impact of age on outcome, a survey by the GIMEMA CML
Working Party. Blood. 2011 May 26;117(21):5591-9.
11. Marzocchi G, Castagnetti F, Luatti S,
Baldazzi C, Stacchini M, Gugliotta G, Amabile M, Specchia G,
Sessarego M, Giussani U, Valori L, Discepoli G, Montaldi A, Santoro
A, Bonaldi L, Giudici G, Cianciulli AM, Giacobbi F, Palandri
F, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G,
Testoni N; Gruppo Italiano Malattie EMatologiche dell'Adulto
(GIMEMA) Working Party on Chronic Myeloid Leukemia. Variant
Philadelphia translocations: molecular-cytogenetic characterization
and prognostic influence on frontline imatinib therapy, a GIMEMA
Working Party on CML analysis. Blood. 2011 Jun
23;117(25):6793-800.
12. Palandri F, Polverelli N,
Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of
leukocytosis on thrombotic risk and survival in 532 patients with
essential thrombocythemia: a retrospective study. Ann Hematol. 2011
Aug;90(8):933-8.
13. Catani L, Sollazzo D, Ricci F,
Polverelli N, Palandri F, Baccarani M,
Vianelli N, Lemoli RM. The CD47 pathway is deregulated in
human immune thrombocytopenia. Exp Hematol. 2011
Apr;39(4):486-94.
14. 11: Castagnetti F, Testoni N, Luatti S,
Marzocchi G, Mancini M, Kerim S, Giugliano E, Albano F, Cuneo A,
Abruzzese E, Martino B, Palandri F, Amabile M, Iacobucci I,
Alimena G, Pane F, Martinelli G, Saglio G, Baccarani M, Rosti G.
Deletions of the derivative chromosome 9 do not influence the
response and the outcome of chronic myeloid leukemia in early
chronic phase treated with imatinib mesylate: GIMEMA CML Working
Party analysis. J Clin Oncol. 2010 Jun 1;28(16):2748-54.
15. Palandri F, Castagnetti F,
Iacobucci I, Martinelli G, Amabile M, Gugliotta G, Poerio A,
Testoni N, Breccia M, Bocchia M, Crugnola M, Rege-Cambrin G,
Martino B, Pierri I, Radaelli F, Specchia G, Pane F, Saglio G,
Rosti G, Baccarani M. The response to imatinib and interferon-alpha
is more rapid than the response to imatinib alone: a retrospective
analysis of 495 Philadelphia-positive chronic myeloid leukemia
patients in early chronic phase. Haematologica. 2010
Aug;95(8):1415-9.
16. Rosti G, Castagnetti F, Gugliotta G,
Palandri F, Martinelli G, Baccarani M. Dasatinib and
nilotinib in imatinib-resistant Philadelphia-positive chronic
myelogenous leukemia: a 'head-to-head comparison'. Leuk
Lymphoma. 2010 Apr;51(4):583-91. Review.
17. Palandri F, Polverelli N,
Ottaviani E, Castagnetti F, Baccarani M, Vianelli N. Long-term
follow-up of essential thrombocythemia in young adults: treatment
strategies, major thrombotic complications and pregnancy outcomes.
A study of 76 patients. Haematologica. 2010
Jun;95(6):1038-40.
18. Baccarani M, Castagnetti F, Gugliotta G,
Palandri F, Soverini S; European Leukemia Net.
Response definitions and European Leukemianet Management
recommendations. Best Pract Res Clin Haematol. 2009
Sep;22(3):331-41. Review.
19. Rosti G, Palandri F, Castagnetti F,
Breccia M, Levato L, Gugliotta G, Capucci A, Cedrone M, Fava C,
Intermesoli T, Cambrin GR, Stagno F, Tiribelli M, Amabile M, Luatti
S, Poerio A, Soverini S, Testoni N, Martinelli G, Alimena G, Pane
F, Saglio G, Baccarani M; GIMEMA CML Working Party.
Nilotinib for the frontline treatment of Ph(+) chronic myeloid
leukemia. Blood. 2009 Dec 3;114(24):4933-8.
20. Palandri F, Castagnetti F,
Soverini S, Poerio A, Gugliotta G, Luatti S, Amabile M, Martinelli
G, Rosti G, Baccarani M. Pancreatic enzyme elevation in chronic
myeloid leukemia patients treated with nilotinib after imatinib
failure. Haematologica. 2009
Dec;94(12):1758-61.
21. Soverini S, Gnani A, Colarossi S,
Castagnetti F, Abruzzese E, Paolini S, Merante S, Orlandi E, de
Matteis S, Gozzini A, Iacobucci I, Palandri F, Gugliotta G,
Papayannidis C, Poerio A, Amabile M, Cilloni D, Rosti G, Baccarani
M, Martinelli G. Philadelphia-positive patients who already harbor
imatinib-resistant Bcr-Abl kinase domain mutations have a higher
likelihood of developing additional mutations associated with
resistance to second- or third-line tyrosine kinase inhibitors.
Blood. 2009 Sep 3;114(10):2168-71.
22. Baldazzi C, Luatti S, Marzocchi G, Stacchini
M, Gamberini C, Castagnetti F, Palandri F, Rosti G,
Baccarani M, Testoni N. Emergence of clonal chromosomal
abnormalities in Philadelphia negative hematopoiesis in chronic
myeloid leukemia patients treated with nilotinib after
failure of imatinib therapy. Leuk Res. 2009
Dec;33(12):e218-20.
23. Breccia M, Palandri F, Iori AP,
Colaci E, Latagliata R, Castagnetti F, Torelli GF, Usai S, Valle V,
Martinelli G, Rosti G, Foà R, Baccarani M, Alimena G.
Second-generation tyrosine kinase inhibitors before allogeneic stem
cell transplantation in patients with chronic myeloid leukemia
resistant to imatinib. Leuk Res. 2010 Feb;34(2):143-7.
24. Baccarani M, Rosti G, Castagnetti F,
Haznedaroglu I, Porkka K, Abruzzese E, Alimena G, Ehrencrona H,
Hjorth-Hansen H, Kairisto V, Levato L, Martinelli G, Nagler A,
Lanng Nielsen J, Ozbek U, Palandri F, Palmieri F, Pane F,
Rege-Cambrin G, Russo D, Specchia G, Testoni N, Weiss-Bjerrum O,
Saglio G, Simonsson B.Comparison of imatinib 400 mg and 800 mg
daily in the front-line treatment of high-risk,
Philadelphia-positive chronic myeloid leukemia: a European
LeukemiaNet Study. Blood. 2009 May 7;113(19):4497-504.
25. Palandri F, Derenzini E,
Ottaviani E, Polverelli N, Catani L, Salmi F, Sabattini E, Bacci F,
Zinzani PL, Baccarani M, Vianelli N. Association of essential
thrombocythemia and non-Hodgkin lymphoma: a single-centre
experience. Leuk Lymphoma. 2009 Mar;50(3):481-4.
26. Palandri F, Ottaviani E, Salmi
F, Catani L, Polverelli N, Fiacchini M, Martinelli G, Baccarani M,
Vianelli N. JAK2 V617F mutation in essential thrombocythemia:
correlation with clinical characteristics, response to therapy and
long-term outcome in a cohort of 275 patients. Leuk
Lymphoma. 2009 Feb;50(2):247-53.
27. Castagnetti F, Palandri F, Amabile M,
Testoni N, Luatti S, Soverini S, Iacobucci I, Breccia M, Rege
Cambrin G, Stagno F, Specchia G, Galieni P, Iuliano F, Pane
F, Saglio G, Alimena G, Martinelli G, Baccarani M, Rosti G; GIMEMA
CML Working Party. Results of high-dose imatinib mesylate in
intermediate Sokal risk chronic myeloid leukemia patients in
early chronic phase: a phase 2 trial of the GIMEMA CML Working
Party. Blood. 2009 Apr 9;113(15):3428-34.
28. Palandri F, Catani L, Testoni
N, Ottaviani E, Polverelli N, Fiacchini M, De Vivo A, Salmi F,
Lucchesi A, Baccarani M, Vianelli N. Long-term follow-up of 386
consecutive patients with essential thrombocythemia: safety of
cytoreductive therapy. Am J Hematol. 2009
Apr;84(4):215-20.
29. Palandri F, Iacobucci I,
Soverini S, Castagnetti F, Poerio A, Testoni N, Alimena G, Breccia
M, Rege-Cambrin G, Tiribelli M, Varaldo R, Abruzzese E, Martino B,
Luciano L, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G.
Treatment of Philadelphia-positive chronic myeloid leukemia with
imatinib: importance of a stable molecular response. Clin Cancer
Res. 2009 Feb1;15(3):1059-63.
30. Palandri F, Castagnetti F,
Alimena G, Testoni N, Breccia M, Luatti S, Rege-Cambrin G, Stagno
F, Specchia G, Martino B, Levato L, Merante S, Liberati AM, Pane F,
Saglio G, Alberti D, Martinelli G, Baccarani M, Rosti G. The
long-term durability of cytogenetic responses in patients with
accelerated phase chronic myeloid leukemia treated with imatinib
600 mg: the GIMEMA CML Working Party experience after a 7-year
follow-up. Haematologica. 2009 Feb;94(2):205-12.
31. Palandri F, Testoni N, Luatti
S, Marzocchi G, Baldazzi C, Stacchini M, Castagnetti F, Breccia M,
Specchia G, Pane F, Saglio G, Martinelli G, Baccarani M, Rosti G.
Influence of additional cytogenetic abnormalities on the response
and survival in late chronic phase chronic myeloid leukemia
patients treated with imatinib: long-term results. Leuk
Lymphoma. 2009 Jan;50(1):114-8.
32. Palandri F, Castagnetti F,
Testoni N, Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G,
Pungolino E, Rege-Cambrin G, Varaldo R, Miglino M, Specchia G,
Zuffa E, Ferrara F, Bocchia M, Saglio G, Pane F, Alberti D,
Martinelli G, Baccarani M, Rosti G; GIMEMA Working Party on Chronic
Myeloid Leukemia. Chronic myeloid leukemia in blast crisis
treated with imatinib 600 mg: outcome of the patients alive after a
6-year follow-up. Haematologica. 2008 Dec;93(12):1792-6.
33. Palandri F, Iacobucci I,
Castagnetti F, Testoni N, Poerio A, Amabile M, Breccia M,
Intermesoli T, Iuliano F, Rege-Cambrin G, Tiribelli M, Miglino M,
Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M; GIMEMA
Working Party on CML. Front-line treatment of Philadelphia
positive chronic myeloid leukemia with imatinib and
interferon-alpha: 5-year outcome. Haematologica. 2008
May;93(5):770-4.
34. Vianelli N, Palandri F, Catani L,
Boschi L, Poggioli G, Giampalma E, Baccarani M. Partial splenic
embolization preceding splenectomy, in a case of refractory immune
thrombocytopenic purpura. Am J Hematol. 2008
Jun;83(6):520.
35. Palandri F, Iacobucci I,
Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S,
Castagnetti F, De Vivo A, Breccia M, Specchia G, Abruzzese E,
Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G,
Baccarani M; GIMEMA Working Party on CML. Long-term outcome
of complete cytogenetic responders after imatinib 400 mg in late
chronic phase, philadelphia-positive chronic myeloid leukemia: the
GIMEMA Working Party on CML. J Clin Oncol. 2008 Jan
1;26(1):106-11.
36. Palandri F, Iacobucci I,
Quarantelli F, Castagnetti F, Cilloni D, Baccarani M; GIMEMA
Working Party on CML. Long-term molecular responses to
imatinib in patients with chronic myeloid leukemia: comparison
between complete cytogenetic responders treated in early and in
late chronic phase. Haematologica. 2007 Nov;92(11):1579-80.
37. Kantarjian HM, Giles F, Gattermann N, Bhalla
K, Alimena G, Palandri F, Ossenkoppele GJ, Nicolini FE,
O'Brien SG, Litzow M, Bhatia R, Cervantes F, Haque A, Shou Y,
Resta DJ, Weitzman A, Hochhaus A, le Coutre P. Nilotinib (formerly
AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is
effective in patients with Philadelphia chromosome-positive chronic
myelogenous leukemia in chronic phase following imatinib resistance
and intolerance. Blood. 2007 Nov 15;110(10):3540-6.
38. Martinelli G, Iacobucci I, Soverini S,
Palandri F, Castagnetti F, Rosti G, Baccarani M. Nilotinib:
a novel encouraging therapeutic option for chronic myeloid leukemia
patients with imatinib resistance or intolerance. Biologics. 2007
Jun;1(2):121-7.
39. Soverini S, Colarossi S, Gnani A,
Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga PP,
Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni N,
Iacobucci I, Cilloni D, Saglio G, Baccarani M, Martinelli G.
Resistance to dasatinib in Philadelphia-positive leukemia patients
and the presence or the selection of mutations at residues 315 and
317 in the BCR-ABL kinase domain. Haematologica. 2007
Mar;92(3):401-4.
40. Rosti G, Iacobucci I, Bassi S, Castagnetti
F, Amabile M, Cilloni D, Poerio A, Soverini S, Palandri F,
Rege Cambrin G, Iuliano F, Alimena G, Latagliata R, Testoni N, Pane
F, Saglio G, Baccarani M, Martinelli G. Impact of age on the
outcome of patients with chronic myeloid leukemia in late chronic
phase: results of a phase II study of the GIMEMA CML Working
Party. Haematologica. 2007 Jan;92(1):101-5.
41. Palandri F, Amabile M, Rosti
G, Bandini G, Benedetti F, Usala E, Angelucci E, Tiribelli M, Fanin
R, Martinelli G, Baccarani M. Imatinib therapy for chronic myeloid
leukemia patients who relapse after allogeneic stem cell
transplantation: a molecular analysis. Bone Marrow
Transplant. 2007 Feb;39(3):189-91.
42. Soverini S, Martinelli G, Colarossi S, Gnani
A, Castagnetti F, Rosti G, Bosi C, Paolini S, Rondoni M, Piccaluga
PP, Palandri F, Giannoulia P, Marzocchi G, Luatti S, Testoni
N, Iacobucci I, Cilloni D, Saglio G, Baccarani M. Presence or the
emergence of a F317L BCR-ABL mutation may be associated with
resistance to dasatinib in Philadelphia chromosome-positive
leukemia. J Clin Oncol. 2006 Nov
20;24(33):e51-2.
43. Bonifazi F, Bandini G, Stanzani M,
Palandri F, Giannini B, Arpinati M, Rosti G, Baccarani M. In
vivo T-cell depletion with low-dose ATG is effective in reducing
cGVHD after peripheral blood stem cell myeloablative sibling
transplants in CML: results from a prospective phase II study. Bone
Marrow Transplant. 2005 May;35(10):1025-6.
44. Palandri F, Bonifazi F, Rossi
C, Falcioni S, Arpinati M, Giannini MB, Ansaloni F, Bandini G,
Baccarani M. Successful treatment of severe hemorrhagic cystitis
with selective vesical artery embolization. Bone Marrow Transplant.
2005 Mar;35(5):529-30.
45. Bacigalupo A, Palandri F. Management
of acute graft versus host disease (GvHD). Hematol J.
2004;5(3):189-96. Review.